Volume 21, Number 9—September 2015
Emerging Infections Program
Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program
||Vaccine effectiveness/efficacy, % (95% CI)
||NCKP trial 2000
|All PCV7 types||Healthy: 96 (93–98); underlying illness: 81 (57–92)||94 (80–98)|
|6B||94 (77–98)||86 (−11 to 100)|
|9V||100 (88–100)||100 (−142 to 100)|
|14||94 (81–98)||100 (60–100)|
|18C||97 (85–99)||100 (49–100)|
|19F||87 (65–95)||85 (32–98)|
|23F||98 (80–100)||100 (15–100)|
*PCV7, 7-valent pneumococcal conjugate vaccine; EIP, Emerging Infections Program; ABCs, Active Bacterial Core Surveillance; NCKP, Northern California Kaiser Permanente; CDC, Centers for Disease Control and Prevention; NA, not available.
- World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. 2013 [cited 2015 Feb 11]. http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/
- Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994;271:1831–5 .
- Langley G, Schaffner W, Farley MM, Lynfield R, Bennett NM, Reingold R, Twenty years of Active Bacterial Core surveillance. Emerg Infect Dis. 2015;21:1520–1528.
- Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis. 1998;26:811–38.
- Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Practical guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–84.
- Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729–35.
- Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001–2003. Clin Infect Dis. 2006;43:141–50.
- Bridges CB, Winquist AG, Fukuda K, Cox NJ, Singleton JA, Strikas RA, Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–38 .
- Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187–95.
- Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–35 .
- Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate caccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362–6.
- Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage—Advisory Committee on Immunization Practices. JAMA. 2002;287:833–4.
- Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb Mortal Wkly Rep. 2004;53:177–8 .
- Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet. 2006;368:1495–502.
- Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003. MMWR Morb Mortal Wkly Rep. 2005;54:893–7 .
- Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–54.
- Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737–46.
- Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043–51.
- Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25:494–501.
- Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine. 2009;27:6483–94.
- Stoecker C, Hampton LM, Link-Gelles R, Messonnier ML, Zhou F, Moore MR. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013;132:e324–32.
- Bergman A, Hjelmgren J, Ortqvist A, Wisloff T, Kristiansen IS, Hogberg LD, Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis. 2008;40:721–9.
- Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012;345:e6879.
- Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784–92.
- Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis. 2002;35:547–55.
- Hampton LM, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison LH, Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205:401–11.
- Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988–95.
- Brueggemann AB, Pai R, Crook D, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 2007;3:e168.
- Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517.
- Porat N, Benisty R, Trefler R, Givon-Lavi N, Dagan R. Clonal distribution of common pneumococcal serotypes not included in the 7-valent conjugate vaccine (PCV7): marked differences between two ethnic populations in southern Israel. J Clin Microbiol. 2012;50:3472–7.
- Song JH, Dagan R, Klugman KP, Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine. 2012;30:2728–37.
- Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013;31:5634–42.
- Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–18 .
- Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–9 and.
- Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep. 2012;61:394–5 .
- Cohen AL, Harrison LH, Farley MM, Reingold AL, Hadler J, Schaffner W, Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS. 2010;24:2253–62.
- Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816–9 .
- Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62:521–4 .
- Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–5 .
- Bonten M, Bolkenbaas M, Huijts S, Webber C, Gault S, Gruber W, Community-acquired pneumonia immunisation trial in adults (CAPITA) [abstract]. Pneumonia. 2014;3:95 [cited 2015 May 21]. https://pneumonia.org.au/index.php/pneumonia/pages/view/isppd
Page created: August 12, 2015
Page updated: August 12, 2015
Page reviewed: August 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.